LinkedIn Corporation (NYSE:LNKD) [Trend Analysis] knocking active thrust in leading trading session, shares a loss of -0.06% to 193.35 with about 1.03 Million shares have changed hands in this session. Russia’s communications regulator ordered public access to LinkedIn’s website to be blocked on Thursday to comply with a court ruling that found the social networking firm guilty of violating data storage laws.
LinkedIn, headquartered in the United States, is the first major social network to be blocked by Russian authorities, setting a precedent for the way foreign Internet firms operate. It has over 6 million registered users in Russia. Russian law requires websites that store the personal data of Russian citizens to do so on Russian servers, something communications regulator Roskomnadzor stated LinkedIn had not done.
LinkedIn’s site will be blocked within 24 hours, the Interfax news agency cited Roskomnadzor spokesman Vadim Ampelonsky as saying. One Internet service provider, Rostelcom, stated it had already blocked access to the site. The stock is going forward its fifty-two week low with 96.79% and lagging behind from its 52-week high price with -24.17%.
Same, the positive performance for the quarter recorded as 0.97% and for the year was -22.27%, while the YTD performance remained at -14.10%. LNKD has Average True Range for 14 days of 1.13.
Moleculin Biotech, Inc. (NASDAQ:MBRX) [Trend Analysis] retains strong position in active trade, as shares scoring 15.38% to $3.03 in a active trade session, while looking at the shares volume, about 241653 shares have changed hands in this session. Moleculin Biotech, (NASDAQ:MBRX) reported it has attained verbal positive guidance from the FDA regarding its planned IND submission indicating that the Firm may incorporate by reference the IND established by a previous developer.
Moleculin’s Chairman and CEO, Walter Klemp, commented, “This new positive guidance removes a major question mark and allows us to create a tighter timeline for the estimated startning of our next clinical trial. To be clear, we still can’t rule out the possibility of a delay in the timeline, but with the knowledge that the FDA is encouraging us to simply incorporate by reference the previous developer’s IND, we believe we can accelerate our IND submission process. On our current path, we expect to be able to file our IND submission before year end. Barring a negative surprise from the FDA’s review of our submission, that should allow us to start treating patients in our next clinical trial several months sooner than predictable.” The firm has institutional ownership of 0.50%, while insider ownership included 39.20%.